Barclays’s Corbus Pharmaceuticals CRBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $240K | Buy |
35,144
+27,142
| +339% | +$251K | ﹤0.01% | 3856 |
|
|
2026
Q2 | $75.1K | Sell |
8,002
-12,780
| -61% | -$121K | ﹤0.01% | 4173 |
|
|
2026
Q1 | $195K | Buy |
20,782
+6,024
| +41% | +$50.7K | ﹤0.01% | 3698 |
|
|
2025
Q4 | $120K | Buy |
14,758
+10,874
| +280% | +$134K | ﹤0.01% | 4525 |
|
|
2025
Q3 | $49.1K | Buy |
3,884
+3,293
| +557% | +$31.3K | ﹤0.01% | 4777 |
|
|
2025
Q2 | $4.08K | Sell |
591
-11,879
| -95% | -$86.3K | ﹤0.01% | 4990 |
|
|
2025
Q1 | $66.2K | Sell |
12,470
-5,686
| -31% | -$50.2K | ﹤0.01% | 4534 |
|
|
2024
Q4 | $214K | Sell |
18,156
-20,306
| -53% | -$341K | ﹤0.01% | 4277 |
|
|
2024
Q3 | $793K | Sell |
38,462
-53,266
| -58% | -$2.73M | ﹤0.01% | 3509 |
|
|
2024
Q2 | $4.15M | Sell |
91,728
-93,420
| -50% | -$3.93M | ﹤0.01% | 1647 |
|
|
2024
Q1 | $7.27M | Buy |
+185,148
| New | +$4.57M | ﹤0.01% | 1605 |
|
|
2022
Q1 | – | Sell |
-1,700
| Closed | -$31K | – | 5045 |
|
|
2021
Q4 | $31K | Sell |
1,700
-487
| -22% | -$13.2K | ﹤0.01% | 3905 |
|
|
2021
Q3 | $68K | Buy |
2,187
+154
| +8% | +$6.07K | ﹤0.01% | 4033 |
|
|
2021
Q2 | $111K | Sell |
2,033
-108
| -5% | -$5.99K | ﹤0.01% | 3807 |
|
|
2021
Q1 | $126K | Buy |
+2,141
| New | +$141K | ﹤0.01% | 3909 |
|
|
2020
Q4 | – | Sell |
-321
| Closed | -$17K | – | 4922 |
|
|
2020
Q3 | $17K | Sell |
321
-895
| -74% | -$162K | ﹤0.01% | 4919 |
|
|
2020
Q2 | $305K | Buy |
1,216
+1,213
| +40,433% | +$245K | ﹤0.01% | 3736 |
|
|
2020
Q1 | $0 | Sell |
3
-1
| -25% | -$169 | ﹤0.01% | 6176 |
|
|
2019
Q4 | $0 | Sell |
4
-1,220
| -100% | -$180K | ﹤0.01% | 6403 |
|
|
2019
Q3 | $179K | Sell |
1,224
-1,176
| -49% | -$205K | ﹤0.01% | 5049 |
|
|
2019
Q2 | $499K | Buy |
2,400
+290
| +14% | +$62.1K | ﹤0.01% | 4321 |
|
|
2019
Q1 | $440K | Buy |
2,110
+1,809
| +601% | +$399K | ﹤0.01% | 4234 |
|
|
2018
Q4 | $52K | Buy |
301
+296
| +5,920% | +$59.1K | ﹤0.01% | 5454 |
|
|
2018
Q3 | $1K | Sell |
5
-358
| -99% | -$57.9K | ﹤0.01% | 7008 |
|
|
2018
Q2 | $54K | Sell |
363
-580
| -62% | -$105K | ﹤0.01% | 5594 |
|
|
2018
Q1 | $172K | Buy |
943
+663
| +237% | +$149K | ﹤0.01% | 4959 |
|
|
2017
Q4 | $60K | Sell |
280
-653
| -70% | -$140K | ﹤0.01% | 5639 |
|
|
2017
Q3 | $200K | Buy |
933
+532
| +133% | +$104K | ﹤0.01% | 4425 |
|
|
2017
Q2 | $76K | Sell |
401
-992
| -71% | -$195K | ﹤0.01% | 5098 |
|
|
2017
Q1 | $345K | Sell |
1,393
-400
| -22% | -$98.2K | ﹤0.01% | 3774 |
|
|
2016
Q4 | $454K | Buy |
+1,793
| New | +$411K | ﹤0.01% | 3458 |
|
Other funds holding CRBP
Barclays's CRBP Position: Q3 2026 in Review
Barclays increased its Corbus Pharmaceuticals (CRBP) stake by 339% in Q3 2026, buying an estimated $251K and bringing the position to 35,144 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3856.
Barclays first reported a position in CRBP in Q4 2016 and has held it in 31 quarters since. The position peaked at $7.27M in Q1 2024. 36 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.
- Barclays held 35,144 shares of Corbus Pharmaceuticals worth $240K as of Q3 2026.
- Barclays bought 27,142 Corbus Pharmaceuticals shares in Q3 2026, an estimated $251K.
- Corbus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3856 holding.
- Barclays first reported a position in Corbus Pharmaceuticals in Q4 2016 and has held it in 31 quarters since.
- Barclays's Corbus Pharmaceuticals position peaked at $7.27M in Q1 2024.
- 36 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.